Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-002698-53 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This dose-escalating study consists of 3 parts (A, B and C) and will evaluate the safety, pharmacokinetics and efficacy of RO5479599, alone or in combination with cetuximab or erlotinib, in participants with metastatic and/or locally advanced malignant HER3-positive solid tumors. Cohorts of participants will receive escalating doses of intravenous RO5479599 as monotherapy (Part A) or in combination with cetuximab (in Part B) or with erlotinib (in Part C) followed by an extension phase for each part.
In an imaging substudy, participants will receive one or two doses of zirconium-89-labeled RO5479599 (89ZrRO5479599) in addition to unlabeled RO5479599 to evaluate the in vivo biodistribution and organ pharmacokinetics of RO5479599.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A: RO5479599 Dose Escalation | Experimental | Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD. |
|
| Part B: RO5479599 Dose Escalation + Cetuximab | Experimental | Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599. |
|
| Part C: RO5479599 Dose Escalation + Erlotinib | Experimental | Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599. |
|
| Imaging (IMG) Substudy | Experimental | RO5479599 will be administered with zirconium- 89-labeled RO5479599. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RO5479599 | Drug | RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Adverse Events | Baseline up to 28 days after last dose (approximately 48 months) | |
| Maximum Tolerated Dose (MTD) or Optimal Biological Dose (OBD) of RO5479599 | Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days | |
| Number of Participants With Dose Limiting Toxicities (DLTs) | Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days | |
| Standardized Uptake Value (SUV) of 89ZrRO5479599 Determined by Positron Emission Tomography (PET) Scan Over Regions of Interest (ROI) | From baseline to Day 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage Change From Baseline in Standardized Uptake Value (SUV) of 89ZrRO5479599 at Pharmacodynamic (PD) active dose as Determined by PET Scan | From baseline to Day 22 | |
| Part A: Recommended Phase II Dose (RPTD) of RO5479599 in Monotherapy | Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days |
Not provided
Inclusion Criteria:
All Parts (A, B and C)
Part B extension cohort: In addition to the above inclusion criteria, participants will be eligible if they have metastatic and/or locally advanced non-small cell lung cancer or squamous cell carcinoma of the head and neck or colorectal cancer (wild type with positive epidermal growth factor receptor [EGFR] expression)
Part C extension cohort: In addition to the above inclusion criteria, participants will be eligible only if they have metastatic and/or locally advanced squamous non-small cell lung cancer
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rigshospitalet, Onkologisk Klinik | København Ø | 2100 | Denmark | |||
| Antoni van Leeuwenhoek Ziekenhuis |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30268483 | Derived | Kim HS, Han JY, Shin DH, Lim KY, Lee GK, Kim JY, Jacob W, Ceppi M, Weisser M, James I. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. Lung Cancer. 2018 Oct;124:71-75. doi: 10.1016/j.lungcan.2018.07.026. Epub 2018 Jul 20. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cetuximab | Drug | Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m^2 for the first infusion, followed by doses of 250 mg/m^2 for subsequent infusions. |
|
| Erlotinib | Drug | Erlotinib, at a dose of 150 mg will be administered. |
|
| zirconium-89-labeled RO5479599 | Drug | Single dose of radiolabeled drug will be administered. |
|
| Part B: Recommended Phase II Dose of RO5479599 in Combination With Cetuximab | Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days |
| Part C: Recommended Phase II Dose of RO5479599 in Combination With Erlotinib | Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days |
| Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 | From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for two weekly schedule [Q2W] and every ninth week for three weekly schedule [Q3W] up to approximately 48 months) |
| Percentage of Participants With Disease Control According to RECIST version 1.1 | From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for Q2W and every ninth week for Q3W up to approximately 48 months) |
| Duration of Response According to RECIST version 1.1 | From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for Q2W and every ninth week for Q3W up to approximately 48 months) |
| Progression Free Survival According to RECIST version 1.1 | From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for Q2W and every ninth week for Q3W up to approximately 48 months) |
| Maximum Serum Concentration (Cmax) of RO5479599 for Q2W Schedule | Pre-infusion (PrI, 0 hours [hr]) & end of infusion (EOI, 1.5 hr) on each 2-week cycle (Cy); 2, 5 hr post-infusion (PoI) on Cy1 Day 1 (D1), Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| Cmax of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Trough Serum Concentration (Cmin) for Q2W Schedule | PreI (0 hr) on D1 of each cycle from Cy2 (up to 48 months overall) (Cycle length = 14 days) |
| Cmin for Q3W Schedule | PreI (0 hr) on D1 of each cycle from Cy2 (up to 48 months overall) (Cycle length = 21 days) |
| Time to Reach Maximum Serum Concentration (Tmax) of RO5479599 for Q2W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| Tmax of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Area Under the Plasma Concentration-Time Curve (AUC) of RO5479599 for Q2W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| AUC of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Clearance (CL) of RO5479599 for Q2W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| CL of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Volume of Distribution (Vd) of RO5479599 for Q2W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| Vd of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Accumulation Ratio of RO5479599 for Q2W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| Accumulation Ratio of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Terminal Elimination Half-Life (t1/2) of RO5479599 for Q2W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| t1/2 of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Serum Concentration of RO5479599 at Time of Tumor Progression (Cprog) for Q2W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall) |
| Cprog of RO5479599 for Q3W Schedule | PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall) |
| Serum Concentration of RO5479599 at the Time of Tumor Response for Q2W Schedule | At the time of objective response (up to 48 months) |
| Serum Concentration of RO5479599 at the Time of Tumor Response for Q3W Schedule | At the time of objective response (up to 48 months) |
| Serum Concentration of RO5479599 at the Time of DLT for Q2W Schedule | At the time of DLT (up to 28 days) |
| Serum Concentration of RO5479599 at the Time of DLT for Q3W Schedule | At the time of DLT (up to 28 days) |
| Serum Concentration of RO5479599 at the Time of Tumor and Skin Biopsy (Cb) for Q2W Schedule | PrI (0 hr) on Cy1D1 and on Cy1 Day 14 (Cycle length = 14 days) |
| Cb of RO5479599 for Q3W Schedule | PrI (0 hr) on Cy1D1 and on Cy1 Day 21 (Cycle length = 21 days) |
| Serum Concentration of RO5479599 at the Time of PET Scan (Cpet) for Q2W Schedule | PrI (0 hr) on Cy1D1, Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days) |
| Cpet of RO5479599 for Q3W Schedule | PrI (0 hr) on Cy1D1, Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days) |
| Serum Concentration of RO5479599 at Time of Infusion-Related Reactions (IRRs) for Q2W Schedule | At the time of IRR (up to 48 months) |
| Serum Concentration of RO5479599 at Time of IRRs for Q3W Schedule | At the time of IRR (up to 48 months) |
| Change from Baseline in T Lymphocytes Cell Count for Q2W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days) |
| Change from Baseline in T lymphocytes Cell Count for Q3W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days) |
| Change from Baseline in Natural Killer Cell Count for Q2W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days) |
| Change from Baseline in Natural Killer Cell Count for Q3W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days) |
| Change from Baseline in Macrophages Cell Count for Q2W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days) |
| Change from Baseline in Macrophages Cell Count for Q3W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days) |
| Change from Baseline in Cytokines Level for Q2W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days) |
| Change from Baseline in Cytokines Level for Q3W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days) |
| Change from Baseline in HER3 Expression for Q2W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days) |
| Change from Baseline in HER3 Expression for Q3W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days) |
| Change from Baseline in Phosphorylated HER3 Expression for Q2W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days) |
| Change from Baseline in Phosphorylated HER3 Expression for Q3W Schedule | PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days) |
| Amsterdam |
| 1066 CX |
| Netherlands |
| Academ Ziekenhuis Groningen; Medical Oncology | Groningen | 9713 GZ | Netherlands |
| Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed | Rotterdam | 3075EA | Netherlands |
| Utrecht University Medical Centre; Dept of Medical Oncology and UPC | Utrecht | 3584 CW | Netherlands |
| National Cancer Center | Gyeonggi-do | 10408 | South Korea |
| Asan Medical Center | Seoul | 05505 | South Korea |
| Hospital del Mar; Servicio de Oncologia | Barcelona | Barcelona | 08003 | Spain |
| Hospital Univ Vall d'Hebron; Servicio de Oncologia | Barcelona | Barcelona | 08035 | Spain |
| Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica | Madrid | Madrid | 28050 | Spain |
| Hospital Universitario Virgen del Rocio; Servicio de Oncologia | Seville | Sevilla | 41013 | Spain |
| Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia | Valencia | Valencia | 46010 | Spain |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000597969 | lumretuzumab |
| D000068818 | Cetuximab |
| D000069347 | Erlotinib Hydrochloride |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D011799 | Quinazolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided